Outcomes using @entity632 -based chemotherapy with or without radiotherapy for early-stage XXXX .

@entity632 @entity1 @entity5 @entity3191 @entity784 @entity2108
There is little information in the literature on outcomes using @entity632 -based chemotherapy with or without radiotherapy for early-stage @entity3191 . The purpose of this study was to analyze The University of Texas M.D. Anderson @entity5 Center results in such @entity1 . From 1985 to 1998, 39 @entity1 with Stage I or II World Health Organization classification @entity2108 ( @entity2108 ; n = 20), @entity3191 , unspecified (PTCLu; n = 11), or nasal-type NK/ @entity784 (NKTCL; n = 8) were treated using @entity632 -based chemotherapy (median, 6 cycles) with (n = 24) or without (n = 15) radiotherapy (median dose, 40 Gy). Median age was 41 years. Median follow-up of surviving @entity1 was 85 months. Even though @entity1 who presented with bulky disease or who achieved less than a complete response to chemotherapy were the ones typically treated with combined modality therapy rather than chemotherapy alone, there was no significant difference in local control (5-year rates: 60 vs. 70%, p = 0.49), progression-free survival (5-year rates: 65 vs. 60%, p = 0.62), or overall survival (5-year rates: 74 vs. 67%, p = 0.47) between the groups treated with combined modality therapy and chemotherapy alone. Fifteen (38%) @entity1 relapsed. Twelve relapses were limited to the initial site of disease; two involved the initial site and new sites, and one involved only new sites. Based on the significant risk of relapse at the initial site of disease, different approaches, including chemotherapy with concomitant radiotherapy to doses > or = 45 Gy, warrant investigation.
